Filing Flows › Retractable Technologies (RVP) › Q2 2026 › vs Q2 2025
Retractable Technologies (RVP) Q2 2026 vs Q2 2025 (year over year)
Retractable Technologies's revenue fell $3.2M (-31%) from $10.4M in Q2 2025 to $7.2M in Q2 2026. The biggest changes: EasyPoint Needles −$3.5M (-85%); Syringes +$322K (+5%); Other Products −$11K (-60%).
Retractable Technologies, Q2 2026: revenue $7.2M (-31% year over year), operating margin -71.5%, net earnings $2.8M, operating cash flow −$1.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Syringes | $6.3M | $5.9M | $322K | +5% |
| EasyPoint Needles | $646K | $4.2M | −$3.5M | -85% |
| Blood Collection Products | $296K | $303K | −$7K | -2% |
| Other Products | $8K | $19K | −$11K | -60% |
| Revenue | $7.2M | $10.4M | −$3.2M | -31% |
| Other income, net | $8.0M | $5.0M | $2.9M | +58% |
| Costs & expenses | $15.2M | $15.6M | −$399K | -3% |
| Operating costs | $12.3M | $15.6M | −$3.2M | -21% |
| Income tax | $2K | $2K | $23 | +1% |
| Net earnings | $2.8M | −$87K | $2.9M | — |
| Cost of revenue | $7.0M | $10.6M | −$3.5M | -34% |
| Research & development | $187K | $160K | $27K | +17% |
| Sales & marketing | $1.5M | $1.7M | −$127K | -8% |
| General & admin | $3.6M | $3.2M | $413K | +13% |
| Operating cash sources | $6.5M | $5.5M | $940K | +17% |
| Depreciation & amortization | $1.9M | $1.9M | $24K | +1% |
| Cash used in operations | $1.7M | $3.7M | −$2.0M | -54% |
| Working capital & other | $6.5M | $5.5M | $940K | +17% |
Questions
How much did Retractable Technologies's revenue grow year over year in Q2 2026?
Retractable Technologies's revenue fell $3.2M (-31%) from $10.4M in Q2 2025 to $7.2M in Q2 2026.
What drove Retractable Technologies's revenue change in Q2 2026?
EasyPoint Needles −$3.5M (-85%); Syringes +$322K (+5%); Other Products −$11K (-60%).